These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 37939656)

  • 21. Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD.
    Schilcher K; Dayoub R; Kubitza M; Riepl J; Klein K; Buechler C; Melter M; Weiss TS
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Targher G; Byrne CD; Tilg H
    Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiscale integrative analyses unveil immune-related diagnostic signature for the progression of MASLD.
    Bai J; Zhu L; Mi W; Gao Z; Ouyang M; Sheng W; Song L; Bao L; Ma Y; Xu Y
    Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37851406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis.
    Lee JH; Park J; Ahn SB
    Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease.
    Li Y; Qi P; Song SY; Wang Y; Wang H; Cao P; Liu Y; Wang Y
    Biomed Pharmacother; 2024 May; 174():116585. PubMed ID: 38615611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions.
    Li M; Larsen FT; van den Heuvel MC; Gier K; Gorter AR; Oosterhuis D; Bijzet J; de Meijer VE; Ravnskjaer K; Nagelkerke A; Olinga P
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.
    Huang Y; Wang Y; Xiao Z; Yao S; Tang Y; Zhou L; Wang Q; Xie Y; Zhang L; Zhou Y; Lu Y; Zhu W; Chen M
    BMC Cardiovasc Disord; 2023 Nov; 23(1):554. PubMed ID: 37951879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis.
    Mladenić K; Lenartić M; Marinović S; Polić B; Wensveen FM
    Eur J Immunol; 2024 Apr; 54(4):e2149641. PubMed ID: 38314819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Ramanathan R; Patwa SA; Ali AH; Ibdah JA
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
    Lai J; Luo L; Zhou T; Feng X; Ye J; Zhong B
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759756
    [No Abstract]   [Full Text] [Related]  

  • 33. Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD.
    Johanns M; Haas JT; Raverdy V; Vandel J; Chevalier-Dubois J; Guille L; Derudas B; Legendre B; Caiazzo R; Verkindt H; Gnemmi V; Leteurtre E; Derhourhi M; Bonnefond A; Froguel P; Eeckhoute J; Lassailly G; Mathurin P; Pattou F; Staels B; Lefebvre P
    JHEP Rep; 2024 Jan; 6(1):100948. PubMed ID: 38125300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Xie C; Liu K; Xie Y; Liu S; Ji B
    Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102264. PubMed ID: 38142587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis.
    Castillo-Núñez Y; Almeda-Valdes P; González-Gálvez G; Arechavaleta-Granell MDR
    Curr Diab Rep; 2024 Jul; 24(7):158-166. PubMed ID: 38700793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
    Gabbia D; De Martin S
    Biology (Basel); 2023 Nov; 12(12):. PubMed ID: 38132297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers.
    Zhang X; Li X; Xiong X
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102230. PubMed ID: 37931846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications.
    Yu L; Gao F; Li Y; Su D; Han L; Li Y; Zhang X; Feng Z
    Biomed Pharmacother; 2024 Jun; 175():116724. PubMed ID: 38761424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.